The new combination product of pertuzumab with trastuzumab together with hyaluronidase (Phesgo, Roche), which can be administered by subcutaneous injection, has been recommended for approval in the ...
Positive recommendation based on clinical, real-world and bioequivalence data supporting feasibility and safety of Phesgo’s administration outside of clinical settings, for example at home1-4 Phesgo ...
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback